Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 28

1.

Validation of Prostate Imaging Reporting and Data System Version 2 for the Detection of Prostate Cancer.

Hofbauer SL, Maxeiner A, Kittner B, Heckmann R, Reimann M, Wiemer L, Asbach P, Haas M, Penzkofer T, Stephan C, Friedersdorff F, Fuller F, Miller K, Cash H.

J Urol. 2018 Oct;200(4):767-773. doi: 10.1016/j.juro.2018.05.003. Epub 2018 May 5.

PMID:
29733838
2.

Primary magnetic resonance imaging/ultrasonography fusion-guided biopsy of the prostate.

Maxeiner A, Kittner B, Blobel C, Wiemer L, Hofbauer SL, Fischer T, Asbach P, Haas M, Penzkofer T, Fuller F, Miller K, Cash H.

BJU Int. 2018 Aug;122(2):211-218. doi: 10.1111/bju.14212. Epub 2018 Apr 17.

PMID:
29569320
3.

Pharmacokinetics, safety and tolerability of an oral suspension of fexofenadine for children with allergic rhinitis.

Segall N, Grubbe RE, Levy AL, Maloney MJ, Nayak AS, Kittner B, Quesada JT.

Allergy Asthma Proc. 2008 Jul-Aug;29(4):380-5. doi: 10.2500/aap.2008.29.3136.

PMID:
18702885
4.

Safety and tolerability of fexofenadine hydrochloride, 15 and 30 mg, twice daily in children aged 6 months to 2 years with allergic rhinitis.

Hampel FC, Kittner B, van Bavel JH.

Ann Allergy Asthma Immunol. 2007 Dec;99(6):549-54. doi: 10.1016/S1081-1206(10)60385-7.

PMID:
18219837
5.

Safety and tolerability of fexofenadine for the treatment of allergic rhinitis in children 2 to 5 years old.

Milgrom H, Kittner B, Lanier R, Hampel FC.

Ann Allergy Asthma Immunol. 2007 Oct;99(4):358-63.

PMID:
17941284
6.
7.

The utility of mixed-effects covariate analysis in rapid selection of doses in pediatric subjects: a case study with fexofenadine hydrochloride.

Krishna R, Krishnaswami S, Kittner B, Sankoh AJ, Jensen BK.

Biopharm Drug Dispos. 2004 Dec;25(9):373-87.

PMID:
15517550
8.

Preliminary results from an MRI/CT-based database for vascular dementia and Alzheimer's disease.

Scheltens P, Kittner B.

Ann N Y Acad Sci. 2000 Apr;903:542-6. No abstract available.

PMID:
10818550
9.
10.

Clinical trials of propentofylline in vascular dementia. European/Canadian Propentofylline Study Group.

Kittner B.

Alzheimer Dis Assoc Disord. 1999 Oct-Dec;13 Suppl 3:S166-71.

PMID:
10609697
11.

Outcome measures for the study of activities of daily living in vascular dementia.

Gauthier S, Rockwood K, Gélinas I, Sykes L, Teunisse S, Orgogozo JM, Erkinjuntti T, Erzigkeit H, Gleeson M, Kittner B, Pontecorvo M, Feldman H, Whitehouse P.

Alzheimer Dis Assoc Disord. 1999 Oct-Dec;13 Suppl 3:S143-7. Review.

PMID:
10609694
12.

Clinical trial designs for demonstrating disease-course-altering effects in dementia.

Whitehouse PJ, Kittner B, Roessner M, Rossor M, Sano M, Thal L, Winblad B.

Alzheimer Dis Assoc Disord. 1998 Dec;12(4):281-94.

PMID:
9876956
13.

Propentofylline in the treatment of vascular dementia and Alzheimer-type dementia: overview of phase I and phase II clinical trials.

Mielke R, Möller HJ, Erkinjuntti T, Rosenkranz B, Rother M, Kittner B.

Alzheimer Dis Assoc Disord. 1998;12 Suppl 2:S29-35. Review.

PMID:
9769027
14.

Propentofylline in the treatment of Alzheimer's disease and vascular dementia: a review of phase III trials.

Rother M, Erkinjuntti T, Roessner M, Kittner B, Marcusson J, Karlsson I.

Dement Geriatr Cogn Disord. 1998 Jul;9 Suppl 1:36-43. Review.

PMID:
9716243
15.

Propentofylline enhances cerebral metabolic response to auditory memory stimulation in Alzheimer's disease.

Mielke R, Ghaemi M, Kessler J, Kittner B, Szelies B, Herholz K, Heiss WD.

J Neurol Sci. 1998 Jan 21;154(1):76-82.

PMID:
9543326
16.

Clinical trials in dementia with propentofylline.

Kittner B, Rössner M, Rother M.

Ann N Y Acad Sci. 1997 Sep 26;826:307-16. Review.

PMID:
9329701
17.

A 12-month, randomized, placebo-controlled trial of propentofylline (HWA 285) in patients with dementia according to DSM III-R. The European Propentofylline Study Group.

Marcusson J, Rother M, Kittner B, Rössner M, Smith RJ, Babic T, Folnegovic-Smalc V, Möller HJ, Labs KH.

Dement Geriatr Cogn Disord. 1997 Sep-Oct;8(5):320-8.

PMID:
9298634
18.

Propentofylline improves regional cerebral glucose metabolism and neuropsychologic performance in vascular dementia.

Mielke R, Kittner B, Ghaemi M, Kessler J, Szelies B, Herholz K, Heiss WD.

J Neurol Sci. 1996 Sep 15;141(1-2):59-64.

PMID:
8880694
19.

HWA 285 (propentofylline)--a new compound for the treatment of both vascular dementia and dementia of the Alzheimer type.

Rother M, Kittner B, Rudolphi K, Rössner M, Labs KH.

Ann N Y Acad Sci. 1996 Jan 17;777:404-9. Review.

PMID:
8624121
20.

Effect of propentofylline on regional cerebral glucose metabolism in acute ischemic stroke.

Huber M, Kittner B, Hojer C, Fink GR, Neveling M, Heiss WD.

J Cereb Blood Flow Metab. 1993 May;13(3):526-30.

PMID:
8478410
21.

Rating scales and computed tomography in multi-infarct dementia.

Folnegović-Smalc V, Mimica N, Makarić G, Loos V, Kittner B, Mimica N.

Neurol Croat. 1992;41(4):183-90.

PMID:
1463803
22.

PC12 cells: a model system for studying drug effects on dopamine synthesis and release.

Kittner B, Bräutigam M, Herken H.

Arch Int Pharmacodyn Ther. 1987 Apr;286(2):181-94.

PMID:
2439033
23.

Apomorphine does not decrease tissue levels of tetrahydrobiopterin in vivo.

Bräutigam M, Kittner B, Herken H.

Eur J Pharmacol. 1986 Aug 7;127(1-2):143-6.

PMID:
3093252
24.

Direct inhibition of tyrosine hydroxylase from PC-12 cells by catechol derivatives.

Laschinski G, Kittner B, Bräutigam M.

Naunyn Schmiedebergs Arch Pharmacol. 1986 Apr;332(4):346-50.

PMID:
2874501
25.

Effects of apomorphine enantiomers and of lisuride on 3,4-dihydroxyphenylalanine production in striatal synaptosomes.

Bräutigam M, Kittner B, Laschinski G.

Mol Pharmacol. 1985 Dec;28(6):515-20.

PMID:
3935908
26.

Effect of apomorphine, alpha-methylparatyrosine, haloperidol and reserpine on DOPA production in clonal cell lines (PC-12 and N1E-115).

Bräutigam M, Laschinski G, Kittner B, Herken H.

Biochem Pharmacol. 1985 Apr 1;34(7):941-7.

PMID:
3921032
27.

Evaluation of neurotropic drug actions on tyrosine hydroxylase activity and dopamine metabolism in clonal cell lines.

Bräutigam M, Kittner B, Herken H.

Arzneimittelforschung. 1985;35(1A):277-84.

PMID:
2859029
28.

Inhibition of striatal tyrosine hydroxylase by low concentrations of apomorphine.

Laschinski G, Kittner B, Bräutigam M.

Naunyn Schmiedebergs Arch Pharmacol. 1984 Sep;327(2):114-8.

PMID:
6149468

Supplemental Content

Loading ...
Support Center